Department of Gynecology,Tianjin Central Hospital of Genecology and Obstetrics,Tianjin 300100,China (Zeng J,Qu PP);Department of Radiation Oncology (Pang QS,Wang PG,Zhang WC,Wang FM),Lymphoma Section (Zhang HL),Tianjin Medical University Cancer Institute and Hospital,Tianjin Key Laboratory of Cancer Prevention and Therapy,National Clinical Research Centre of Cancer,Tianjin 300060,China
Abstract：Objective To retrospectively analyze the treatment outcomes and prognostic factors for primary bone lymphomas (PBL). Methods Forty patients with PBL who were admitted to our center from 1964 to 2014 were enrolled as subjects. In those patients, 10 were treated with chemotherapy alone, 10 with radiochemotherapy, 10 with postoperative chemotherapy, 9 with postoperative radiochemotherapy, and 1 with surgery alone. The median radiation dose was 36 Gy. The Kaplan-Meier method was used to calculate survivalrates. The log-rank test was used for survival difference analysis and univariate prognostic analysis. Results The follow-up rate was 100%. The 3-year sample size was 36. In all patients, the 1-and 3-year overall survival rates were 60% and 42%, respectively, while the 1-and 3-year disease-free survival rates were 45% and 34%, respectively. The univariate analysis showed that no pathological fracture at diagnosis, normal lactate dehydrogenase level, an International Prognostic Index score of ≤1, early clinical stage (stage ⅠE), complete response after initial treatment, no less than 6 cycles of chemotherapy, a radiation dose of ≥40 Gy, no progression outside radiation field after radiotherapy, and grade<3 bone marrow suppression during the treatment were prognostic factors for survival (P=0.027, 0.037, 0.000, 0.016, 0.000, 0.000, 0.022, 0.014, and 0.030). Conclusions The incidence of PBL is low. Comprehensive treatment can achieve satisfactory outcomes. As a PBL staging system, Ann Arbor has limitations. The staging of PBL should be based on local bone destruction and metastasis.
Zeng Jing,Pang Qingsong,Zhang Huilai et al. Prognosis and staging of primary bone lymphoma:an analysis of 40 patients[J]. Chinese Journal of Radiation Oncology, 2016, 25(8): 843-846.
[1] Lakshmaiah K,Guruprasad B,Purohit S,et al. Primary non-Hodgkin′s lymphoma of bone:poly-ostotic versus mono-ostotic subtypes[J].Ecancermedicalscience,2013,7:330.DOI:10.3332/ecancer.2013.330 [2] Jo VY,Fletcher CD.WHO classification of soft tissue tumours:an update based on the 2013(4th) edition[J].Pathology,2014,46(2):95-104.DOI:10.1097/PAT.0000000000000050 [3] Cheson BD,Pfistner B,Juweid ME,et al. Revised response criteria for malignant lymphoma[J].J Clin Oncol,2007,25(5):579-586.DOI:10.1200/JCO.2006.09.2403 [4] Jones D,Kraus MD,Dorfman DM.Lymphoma presenting as a solitary bone lesion[J].Am J Clin Pathol,1999,111(2):171-178 [5] Heyning FH,Hogendoorn PC,Kramer MH,et al. Primary non-Hodgkin′s lymphoma of bone:a clinicopathological investigation of60 cases[J].Leukemia,1999,13(12):2094-2098 [6] Mendenhall NP,Jones JJ,Kramer BS,et al. The management of primary lymphoma of bone[J].Radiother Oncol,1987,9(2):137-145 [7] 吴鹏强,赵春燕,韩丽英,等.淋巴瘤患者血清乳酸脱氢酶检测的临床意义[J].泸州医学院学报,2006(01):22-23.DOI:10.3969/j.issn.1000-2669.2006.01.008 Wu PQ,Zhao CHY,Han LY,et al. Clinical significance of detection of serum lactate dehydrogenase in patients with lymphoma[J].J Luzhou Med College,2006(01):22-23.DOI:10.3969/j.issn.1000-2669.2006.01.008 [8] Benboubker L,Valat C,Linassier C,et al. A new serologic index for low-grade non-Hodgkin′s lymphoma based on initial CA125 and LDH serum levels[J].Ann Oncol,2000,11(11):1485-1491 [9] A predictive model for aggressive non-Hodgkin′s lymphoma. The International non-Hodgkin′s lymphoma prognostic factors project[J].N Engl J Med,1993,329(14):987-994 [10] Ramadan KM,Shenkier T,Sehn LH,et al. A clinicopathological retrospective study of 131 patients with primary bone lymphoma:a population-based study of successively treated cohorts from the British columbia cancer agency[J].Ann Oncol,2007,18(1):129-135.DOI:10.1093/annonc/mdl329 [11] 温戈,王汉渝,张玉晶,等.原发性骨淋巴瘤的疗效和预后因素分析[J].中华放射肿瘤学杂志,2011,20(4):313-316.DOI:10.3760/cma.j.issn.1004-4221.2011.04.015 Wen G,Wang HY,Zhang YJ,et al. Analysis of the curative effect and prognostic factors of primary lymphoma of bone[J].Chin J Radiat Oncol,2011,20(4):313-316.DOI:10.3760/cma.j.issn.1004-4221.2011.04.015 [12] Dubey P,Ha CS,Besa PC,et al. Localized primary malignant lymphoma of bone[J].Int J Radiat Oncol Biol Phys,1997,37(5):1087-1093 [13] 黄一容,顾大中,王奇璐,等.恶性淋巴瘤的综合治疗[J].中华放射肿瘤学杂志,1997,6(2):77-79 Huang YR,Gu DZH,Wang QL,et al. Comprehensive treatment of malignant lymphomaComprehensive treatment of malignant lymphoma[J].Chin J Radiat Oncol,1997,6(2):77-79
2016, Vol. 25 
